Skip to navigation menu Skip to content


Bacteriophages (phages) have been minimally used in emergency clinical applications for skin and soft tissue infections and disseminated bacterial infections, but not to-date as an aerosol strategy against pulmonary mycobacteria. One limitation in the field preventing these advancements is the availability of a reproducible preclinical model of aerosol phage delivery that can be leveraged for efficacy testing. Importantly, our preliminary proof-of-concept results1 (read the paper) suggest that aerosol delivery of phage to mice can significantly reduce bacterial burden after challenge with M.tb. 

Our lab is actively collaborating to develop reproducible aerosol models of delivery and answer longstanding biological questions about phage treatment in vivo. This includes basic host immunological outcomes of repeated phage treatment, route of delivery and pharmacodynamics/kinetics. This work is done extensively in partnership with the Hatfull Lab at the University of Pittsburg, and has been supported through NIAID grant funding.

  1. Carrigy NB, Larsen SE, Reese V, Pecor T, Harrison M, Kuehl PJ, Hatfull GF, Sauvageau D, Baldwin SL, Finlay WH, Coler RN, Vehring R. Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29Antimicrob Agents Chemother. 2019 Sep 16;63(12):e00871-19. doi: 10.1128/AAC.00871-19. Epub ahead of print. PMID: 31527037; PMCID: PMC6879268.

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in marketing efforts. For more information, see Website Privacy.

Accept All Cookies